Cantanhede, Portugal

Daniel Vargas Correia

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2021-2024

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: **A Glimpse into the Innovations of Daniel Vargas Correia**

Introduction

Daniel Vargas Correia, an innovative thinker from Cantanhede, Portugal, has made significant contributions to the field of immunology. With three patents to his name, Daniel's work primarily focuses on the production and clinical application of TCR gamma delta T cells, showcasing his commitment to advancing medical science.

Latest Patents

Among his latest innovations, Daniel holds patents for methods related to the production of TCR gamma delta T cells. These inventions detail novel processes for the isolation and selective ex vivo expansion of V32' TCRy6+ T cells, reflecting a keen understanding of cellular expansion techniques and their potential clinical applications.

Career Highlights

Daniel has collaborated with leading organizations in the biotechnology sector, including Gammadelta Therapeutics Ltd and Lymphact—Lymphocyte Activation Technologies, S.A. His experiences in these companies have greatly enhanced his expertise in developing cutting-edge immunotherapies.

Collaborations

Throughout his career, Daniel has worked closely with esteemed colleagues such as Diogo Antonio Remechido Anjos and Afonso Rocha Martins De Almeida. These collaborations have undoubtedly enriched his research endeavors, leading to impactful advancements in their shared field of study.

Conclusion

Daniel Vargas Correia exemplifies the spirit of innovation. His contributions to immunology and his impressive patent portfolio illustrate his dedication to improving treatments and outcomes for patients. As he continues to push the boundaries of medical research, the impact of his work will be felt for years to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…